MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100 mouse
about
Salivary biomarkers for detection of systemic diseasesPlasma cholesterol-induced lesion networks activated before regression of early, mature, and advanced atherosclerosis.Matrix metalloproteinases in atherosclerosis: role of nitric oxide, hydrogen sulfide, homocysteine, and polymorphisms.Matrix metalloproteinases promote arterial remodeling in aging, hypertension, and atherosclerosisModulation of recombinant antigenic constructs containing multi-epitopes towards effective reduction of atherosclerotic lesion in B6;129S-Ldlr(tm1Her)Apob(tm2Sgy)/J miceInsulin resistance promotes early atherosclerosis via increased proinflammatory proteins and oxidative stress in fructose-fed ApoE-KO mice.Elevated concentrations of serum matrix metalloproteinase-2 and -9 and their associations with circulating markers of cardiovascular diseases in chronic arsenic-exposed individuals.Tissue Inhibitor of Metalloproteinase-1: Actions beyond Matrix Metalloproteinase Inhibition.Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism.Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing inflammation and oxidative stress.Using plasma matrix metalloproteinase-9 and monocyte chemoattractant protein-1 to predict future cardiovascular events in subjects with carotid atherosclerosis.Aspirin suppresses TNF-α-induced MMP-9 expression via NF-κB and MAPK signaling pathways in RAW264.7 cells.Gastrin-releasing peptide promotes the migration of vascular smooth muscle cells through upregulation of matrix metalloproteinase-2 and -9.
P2860
Q34700220-FD3F975A-89EF-461C-97CF-3F92C071B40AQ35105781-68779FE7-3EE7-4BEE-8836-EB4B38003CC0Q35161646-C5526879-A09D-4ADC-AE8B-A1736AE7EE36Q35175533-49C242B7-62FE-4F47-A544-80987AFC32F6Q35591762-352655FE-D0C2-4E80-887C-5F058CB98E39Q35845997-7A21175A-4559-4EBE-91C9-3E59D6A27D8BQ36348607-1CDE8056-086E-4B6E-AF40-7D5AD87286CBQ36526033-9163995A-A43C-4587-A3AB-671CEB3482ECQ37380847-2E70DC85-CD51-469C-B001-A3E78A5CD253Q37434796-6997724A-FBB2-47E5-AD69-FCAD995C99D0Q37578873-A5528E83-E822-43A7-AE5E-8C0BB84EDBE9Q37736555-E1771B59-E5A5-4144-B003-8CF69E07FC6BQ39277249-B9261559-5E82-45C3-BE5E-E4042F56DF51Q47102444-ADADD9F7-979D-438D-A863-11E338AB16ECQ47609299-523C925E-906E-4B6D-8BCC-8C536942268F
P2860
MMP-2 and MMP-9 are prominent matrix metalloproteinases during atherosclerosis development in the Ldlr-/-Apob100/100 mouse
description
article
@en
im Mai 2011 veröffentlichter wissenschaftlicher Artikel
@de
wetenschappelijk artikel
@nl
наукова стаття, опублікована в травні 2011
@uk
name
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@en
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@nl
type
label
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@en
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@nl
prefLabel
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@en
MMP-2 and MMP-9 are prominent ...... n the Ldlr-/-Apob100/100 mouse
@nl
P2093
P356
P1476
MMP-2 and MMP-9 are prominent ...... e Ldlr(-/-)Apob(100/100) mouse
@en
P2093
Chaoyong Zhu
Dick Wågsäter
Johan Björkegren
Josefin Skogsberg
P304
P356
10.3892/IJMM.2011.693
P50
P577
2011-05-06T00:00:00Z